Article
A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Journal of biomolecular screening - 1 Feb 2016
Leveridge Melanie, Collier Lee, Edge Colin, Hardwicke Phil, Leavens Bill, Ratcliffe Steve, Rees Mike, Stasi Luigi Piero, Nadin Alan, Reith Alastair D
Abstract excerpt
LRRK2 is a large multidomain protein containing two functional enzymatic domains: a GTPase domain and a protein kinase domain. Dominant coding mutations in the LRRK2 protein are associated with Parkinson's disease (PD). Among such pathogenic mutations, Gly2019Ser mutation in the LRRK2 kinase domain is the most frequent cause of familial PD in Caucasians and is also found in some apparently sporadic PD cases. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.